ChromaDex Co. (NASDAQ:CDXC) Stock Position Lessened by Tieton Capital Management LLC

Tieton Capital Management LLC trimmed its stake in shares of ChromaDex Co. (NASDAQ:CDXC) by 0.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,956,120 shares of the company’s stock after selling 11,940 shares during the period. ChromaDex makes up 5.6% of Tieton Capital Management LLC’s investment portfolio, making the stock its 4th largest holding. Tieton Capital Management LLC’s holdings in ChromaDex were worth $10,790,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex during the 2nd quarter valued at about $597,000. Bank of New York Mellon Corp increased its holdings in ChromaDex by 170.0% during the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the last quarter. BSW Wealth Partners bought a new position in ChromaDex in the third quarter worth approximately $324,000. Rhumbline Advisers purchased a new position in shares of ChromaDex during the 2nd quarter worth $124,000. Finally, Perritt Capital Management Inc. bought a new stake in shares of ChromaDex during the 1st quarter valued at $139,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Stock Performance

Shares of ChromaDex stock opened at $7.44 on Friday. The company has a fifty day moving average of $4.53 and a 200 day moving average of $3.56. The company has a market capitalization of $568.27 million, a P/E ratio of 744.74 and a beta of 1.88. ChromaDex Co. has a fifty-two week low of $1.32 and a fifty-two week high of $7.85.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same period in the previous year, the firm earned ($0.01) EPS. Analysts forecast that ChromaDex Co. will post 0.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Monday, November 18th. Roth Mkm lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.